{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:10:06Z","timestamp":1782835806759,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s11914-016-0337-9","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T01:19:03Z","timestamp":1475630343000},"page":"345-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health"],"prefix":"10.1007","volume":"14","author":[{"given":"Andrea","family":"Egger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius E.","family":"Kraenzlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"issue":"21","key":"337_CR1","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1001\/jama.2011.715","volume":"305","author":"AV Schwartz","year":"2011","unstructured":"Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):2184\u201392.","journal-title":"JAMA"},{"issue":"5","key":"337_CR2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrendo.2011.233","volume":"8","author":"C Hamann","year":"2012","unstructured":"Hamann C, Kirschner S, Gunther KP, Hofbauer LC. Bone, sweet bone\u2014osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol. 2012;8(5):297\u2013305.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"337_CR3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","volume":"18","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2014a meta-analysis. Osteoporos Int. 2007;18(4):427\u201344.","journal-title":"Osteoporos Int"},{"key":"337_CR4","doi-asserted-by":"crossref","unstructured":"Schwartz AV. Epidemiology of fractures in type 2 diabetes. Bone. 2015","DOI":"10.1016\/j.bone.2015.05.032"},{"issue":"8","key":"337_CR5","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.2337\/dc10-0067","volume":"33","author":"WP Koh","year":"2010","unstructured":"Koh WP, Wang R, Ang LW, Heng D, Yuan JM, Yu MC. Diabetes and risk of hip fracture in the Singapore Chinese health study. Diabetes Care. 2010;33(8):1766\u201370.","journal-title":"Diabetes Care"},{"issue":"7","key":"337_CR6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/jbmr.2462","volume":"30","author":"CI Li","year":"2015","unstructured":"Li CI, Liu CS, Lin WY, et al. Glycated hemoglobin level and risk of Hip fracture in older people with type 2 diabetes: a competing risk analysis of Taiwan diabetes cohort study. J Bone Miner Res. 2015;30(7):1338\u201346.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"337_CR7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495\u2013505.","journal-title":"Am J Epidemiol"},{"key":"337_CR8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bone.2015.04.026","volume":"82","author":"C Meier","year":"2016","unstructured":"Meier C, Schwartz AV, Egger A, Lecka-Czernik B. Effects of diabetes drugs on the skeleton. Bone. 2016;82:93\u2013100.","journal-title":"Bone"},{"issue":"11","key":"337_CR9","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/jbmr.1759","volume":"27","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012;27(11):2231\u20137.","journal-title":"J Bone Miner Res"},{"issue":"11-12","key":"337_CR10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","volume":"36","author":"CF Deacon","year":"2004","unstructured":"Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36(11-12):761\u20135.","journal-title":"Horm Metab Res"},{"issue":"1","key":"337_CR11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/apt.12092","volume":"37","author":"P Janssen","year":"2013","unstructured":"Janssen P, Rotondo A, Mule F, Tack J. Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2013;37(1):18\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"337_CR12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-physiol-021113-170317","volume":"76","author":"DJ Drucker","year":"2014","unstructured":"Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561\u201383.","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"337_CR13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/edrv.20.6.0385","volume":"20","author":"TJ Kieffer","year":"1999","unstructured":"Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876\u2013913.","journal-title":"Endocr Rev"},{"issue":"6","key":"337_CR14","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131\u201357.","journal-title":"Gastroenterology"},{"issue":"2","key":"337_CR15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1210\/en.2007-1292","volume":"149","author":"C Yamada","year":"2008","unstructured":"Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008;149(2):574\u20139.","journal-title":"Endocrinology"},{"issue":"5","key":"337_CR16","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.bone.2007.01.007","volume":"40","author":"D Xie","year":"2007","unstructured":"Xie D, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone. 2007;40(5):1352\u201360.","journal-title":"Bone"},{"issue":"2","key":"337_CR17","doi-asserted-by":"crossref","first-page":"E543","DOI":"10.1152\/ajpendo.00364.2006","volume":"292","author":"Q Zhong","year":"2007","unstructured":"Zhong Q, Itokawa T, Sridhar S, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2007;292(2):E543\u2013548.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"337_CR18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bone.2006.09.025","volume":"40","author":"DB Henriksen","year":"2007","unstructured":"Henriksen DB, Alexandersen P, Hartmann B, et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone. 2007;40(3):723\u20139.","journal-title":"Bone"},{"issue":"1","key":"337_CR19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.abb.2010.06.020","volume":"503","author":"JS Walsh","year":"2010","unstructured":"Walsh JS, Henriksen DB. Feeding and bone. Arch Biochem Biophys. 2010;503(1):11\u20139.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"337_CR20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bone.2003.09.009","volume":"34","author":"DB Henriksen","year":"2004","unstructured":"Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone. 2004;34(1):140\u20137.","journal-title":"Bone"},{"issue":"5","key":"337_CR21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2009.07.008","volume":"45","author":"DB Henriksen","year":"2009","unstructured":"Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009;45(5):833\u201342.","journal-title":"Bone"},{"issue":"1","key":"337_CR22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139. Guidelines for the treatment of type 2 diabetes including the results of the latest studies.","journal-title":"Diabetes Care"},{"issue":"4","key":"337_CR23","first-page":"401","volume":"4","author":"LL Nielsen","year":"2003","unstructured":"Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2003;4(4):401\u20135.","journal-title":"Curr Opin Investig Drugs"},{"issue":"7","key":"337_CR24","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jbmr.1898","volume":"28","author":"X Ma","year":"2013","unstructured":"Ma X, Meng J, Jia M, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res. 2013;28(7):1641\u201352.","journal-title":"J Bone Miner Res"},{"key":"337_CR25","doi-asserted-by":"crossref","unstructured":"Meng J, Ma X, Wang N, et al. Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through beta-Catenin. Stem Cell Rep. 2016.","DOI":"10.1016\/j.stemcr.2016.03.010"},{"issue":"7","key":"337_CR26","doi-asserted-by":"crossref","first-page":"e0132744","DOI":"10.1371\/journal.pone.0132744","volume":"10","author":"N Lu","year":"2015","unstructured":"Lu N, Sun H, Yu J, et al. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS One. 2015;10(7):e0132744.","journal-title":"PLoS One"},{"key":"337_CR27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bone.2015.08.006","volume":"81","author":"M Pereira","year":"2015","unstructured":"Pereira M, Jeyabalan J, Jorgensen CS, et al. Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone. 2015;81:459\u201367.","journal-title":"Bone"},{"issue":"4","key":"337_CR28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","volume":"13","author":"MC Bunck","year":"2011","unstructured":"Bunck MC, Eliasson B, Corner A, et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):374\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"337_CR29","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1210\/jc.2015-1176","volume":"100","author":"EW Iepsen","year":"2015","unstructured":"Iepsen EW, Lundgren JR, Hartmann B, et al. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab. 2015;100(8):2909\u201317. A randomized controlled trial examining changes in bone mineral content and bone markers after 52-week weight maintenance with or without GLP-1 RA treatment. The study was of great interest and was discussed controversially through letters to the editor by two other research groups.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"337_CR30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1753-0407.12102","volume":"6","author":"G Mabilleau","year":"2014","unstructured":"Mabilleau G, Mieczkowska A, Chappard D. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes. 2014;6(3):260\u20136.","journal-title":"J Diabetes"},{"issue":"1","key":"337_CR31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-014-0361-4","volume":"48","author":"B Su","year":"2015","unstructured":"Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists\u2019 treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48(1):107\u201315.","journal-title":"Endocrine"},{"issue":"5","key":"337_CR32","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00223-015-0037-y","volume":"97","author":"JH Driessen","year":"2015","unstructured":"Driessen JH, van Onzenoort HA, Starup-Linde J, et al. Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs. Calcif Tissue Int. 2015;97(5):506\u201315.","journal-title":"Calcif Tissue Int"},{"key":"337_CR33","doi-asserted-by":"crossref","unstructured":"Glorie L, Behets GJ, Baerts L, De Meester I, D\u2019Haese PC, Verhulst A. DPP4 inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J Physiol Endocrinol Metab. 2014.","DOI":"10.1152\/ajpendo.00217.2014"},{"issue":"3","key":"337_CR34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/dmrr.2466","volume":"30","author":"EJ Gallagher","year":"2014","unstructured":"Gallagher EJ, Sun H, Kornhauser C, et al. The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev. 2014;30(3):191\u2013200.","journal-title":"Diabetes Metab Res Rev"},{"issue":"11","key":"337_CR35","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","volume":"34","author":"M Monami","year":"2011","unstructured":"Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474\u20136.","journal-title":"Diabetes Care"},{"key":"337_CR36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bone.2014.07.030","volume":"68","author":"JH Driessen","year":"2014","unstructured":"Driessen JH, van Onzenoort HA, Henry RM, et al. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone. 2014;68:124\u201330.","journal-title":"Bone"},{"issue":"4","key":"337_CR37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262\u201374.","journal-title":"Ann Intern Med"},{"issue":"7","key":"337_CR38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao EC, Henry RR. SGLT2 inhibition\u2014a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551\u20139.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"337_CR39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","volume":"61","author":"V Gorboulev","year":"2012","unstructured":"Gorboulev V, Schurmann A, Vallon V, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012;61(1):187\u201396.","journal-title":"Diabetes"},{"issue":"6","key":"337_CR40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2133\/dmpk.20.452","volume":"20","author":"M Nishimura","year":"2005","unstructured":"Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005;20(6):452\u201377.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"337_CR41","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.2040-1124.2012.00227.x","volume":"3","author":"N Harada","year":"2012","unstructured":"Harada N, Inagaki N. Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J Diabetes Investig. 2012;3(4):352\u20133.","journal-title":"J Diabetes Investig"},{"issue":"22","key":"337_CR42","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. Randomized controlled trial including over 7000 type 2 diabetics with increased risk for cardiovascular disease. The addition of empagliflozin to standard care leads to a lower rate of the primary composite cardiovascular outcome and of death. The article seems to be a milestone paper, promoting the application of SGLT-2 inhibitors.","journal-title":"N Engl J Med"},{"key":"337_CR43","doi-asserted-by":"crossref","unstructured":"Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabet Endocrinol. 2016.","DOI":"10.1016\/S2213-8587(16)00052-8"},{"issue":"1","key":"337_CR44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","volume":"3","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3(1):8\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"337_CR45","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrendo.2011.218","volume":"8","author":"LD Quarles","year":"2012","unstructured":"Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol. 2012;8(5):276\u201386.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"337_CR46","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","volume":"34","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015\u201322.","journal-title":"Diabetes Care"},{"issue":"4","key":"337_CR47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"JF List","year":"2009","unstructured":"List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650\u20137.","journal-title":"Diabetes Care"},{"issue":"11","key":"337_CR48","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","volume":"14","author":"O Ljunggren","year":"2012","unstructured":"Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14(11):990\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"337_CR49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101(1):44\u201351. A randomized controlled multicenter study including 700 patients. It showed a possible negative effect of the use of SGLT-2 inhibitors on BMD and therefore puts the advantages of the new drugs into perspective.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"337_CR50","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232\u20138.","journal-title":"Diabetes Care"},{"issue":"4","key":"337_CR51","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/oby.20663","volume":"22","author":"HE Bays","year":"2014","unstructured":"Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014;22(4):1042\u20139.","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"337_CR52","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1530\/acta.0.1290393","volume":"129","author":"L Hyldstrup","year":"1993","unstructured":"Hyldstrup L, Andersen T, McNair P, Breum L, Transbol I. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction. Acta Endocrinol (Copenh). 1993;129(5):393\u20138.","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"6","key":"337_CR53","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bone.2011.08.026","volume":"49","author":"K Bleicher","year":"2011","unstructured":"Bleicher K, Cumming RG, Naganathan V, et al. The role of fat and lean mass in bone loss in older men: findings from the CHAMP study. Bone. 2011;49(6):1299\u2013305.","journal-title":"Bone"},{"issue":"3","key":"337_CR54","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/jbmr.1483","volume":"27","author":"AV Schwartz","year":"2012","unstructured":"Schwartz AV, Johnson KC, Kahn SE, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res. 2012;27(3):619\u201327.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"337_CR55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.2754","volume":"31","author":"AL Schafer","year":"2016","unstructured":"Schafer AL. Decline in bone mass during weight loss: a cause for concern? J Bone Miner Res. 2016;31(1):36\u20139.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"337_CR56","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/jbmr.2564","volume":"30","author":"J Zibellini","year":"2015","unstructured":"Zibellini J, Seimon RV, Lee CM, et al. Does diet-induced weight loss lead to bone loss in overweight or obese adults? a systematic review and meta-analysis of clinical trials. J Bone Miner Res. 2015;30(12):2168\u201378.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"337_CR57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jbmr.2701","volume":"31","author":"DT Villareal","year":"2016","unstructured":"Villareal DT, Fontana L, Das SK, et al. Effect of two-year caloric restriction on bone metabolism and bone mineral density in non-obese younger adults: a randomized clinical trial. J Bone Miner Res. 2016;31(1):40\u201351.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"337_CR58","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962\u201371.","journal-title":"Kidney Int"},{"issue":"1","key":"337_CR59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101(1):157\u201366.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"337_CR60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2014a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217\u201323. e211.","journal-title":"Am Heart J"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-016-0337-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-016-0337-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-016-0337-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T04:21:15Z","timestamp":1568434875000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-016-0337-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1007\/s11914-016-0337-9","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]}}}